The FDA approved tavapadon (Juvmo), a new Parkinson's drug developed by AbbVie that takes a different approach by targeting D1 and D5 dopamine receptors instead of the D2 receptors used by existing treatments. Clinical trials showed the once-daily pill produced significant improvements in movement and daily functioning, with about 45-46% of patients reporting marked improvement compared to 12-19% on placebo. The drug was designed to avoid side effects of earlier D1-targeting compounds by being resistant to enzymatic breakdown and providing only partial receptor activation.